Compare BioNTech SE - ADR (BNTX) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Orion Office REIT Inc — how do they compare? BioNTech SE - ADR trades at $93.04 (market cap $23.31B), while Orion Office REIT Inc trades at $2.79 (market cap $158.01M). The key difference: BioNTech SE - ADR is far larger — about 147.5× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.89% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | ONL | |
|---|---|---|
Market Cap | $23.31B | $158.01M |
Sector | Health | Real Estate |
52-Week High | $119.34 | $3.04 |
52-Week Low | $83.89 | $1.93 |
Enterprise Value | $6.60B | $574.95M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
ONL trades at $2.80, up 1.82% with a bullish technical signal. The company reported mixed Q2 2026 results with an EPS beat but faces fundamental challenges including declining revenue and negative net income margins. Analyst consensus is split 50/50 between Buy and Hold ratings. Recent news highlights strategic review progress and portfolio repositioning efforts.
Outlook remains cautious due to persistent losses and revenue decline, though low P/B ratio and dividend payments offer some value. Key risks include continued negative profitability and high debt levels. The stock presents speculative value for investors tolerant of turnaround execution risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
